Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

4.66
Delayed Data
As of Jan 22
 +0.02 / +0.43%
Today’s Change
3.42
Today|||52-Week Range
6.37
-8.45%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 3
2018
Quarter 4
2018
Quarter 1
2019
Quarter 2
2019
Revenue and IncomeNet Revenues5.3M3.2M4.3M10.0M
 
 
 
 
 
Cost of Goods Sold------493.0K
 
 
Depreciation And Amortization424.0K483.0K557.0K--
 
 
 
 
 
Operating ExpensesGross Income------9.5M
 
 
General Expenses14.7M17.2M21.1M27.7M
 
 
 
 
 
Research And Development8.1M9.6M12.4M13.1M
 
 
 
 
 
Total Operating Expenses15.2M17.7M21.6M28.1M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-9.8M-14.5M-17.3M-18.2M
 
 
 
 
 
Extraordinary Credit8.0M0.000.00916.0K
 
 
 
Extraordinary Charge-23.2M-100.0K-900.0K--
 
 
 
 
Interest Expense On Debt1.2M1.2M1.1M607.0K
 
 
 
 
 
Other Expenses-92.0K208.0K-71.0K--
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-25.8M-14.8M-18.7M-19.7M
 
 
 
 
 
Income Taxes-1.5M-83.0K0.000.00
 
 
 
Net Income-24.4M-14.7M-18.7M-19.7M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS80.3M84.5M84.5M85.0M
 
 
 
 
 
Shares To Calculate EPS Diluted80.3M84.5M84.5M85.0M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.30-$0.17-$0.22-$0.23
 
 
 
 
 
EPS Diluted-$0.30-$0.17-$0.22-$0.23